Economic Assessment of Thrombocytopenia: CATCH Registry
详细信息 查看全文
- 作者：Eric L. Eisenstein ; Emily F. Honeycutt ; Kevin J. Anstrom ; Richard C. Becker ; Christopher B. Granger ; Sunil V. Rao ; Marc E. Jolicoeur ; E. Magnus Ohman and for the CATCH Investigators
- 关键词：Heparin ; Thrombocytopenia ; Cost of Illness ; Registry ; Economic Analysis
- 刊名：Journal of Medical Systems
- 出版年：2010
- 出版时间：June, 2010
- 年：2010
- 卷：34
- 期：3
- 页码：379-386
- 全文大小：192.7 KB
文摘
Thrombocytopenia is associated with increased patient risk. However, the costs of this complication are not well defined. This study assessed the impact of thrombocytopenia on in-hospital costs using results from CATCH, an observational study that examined 1988 consecutive patients receiving prolonged heparin therapy (≥96 h). Thrombocytopenia was defined as: (group 1) an absolute reduction in platelet count to <150 ¡Á 109/L; (group 2) a relative reduction in platelet count of >50 % from admission levels; or (group 3) both criteria. We found that the development of thrombocytopenia was associated with significantly higher total in-hospital costs for all groups: (group 1) (difference, $8,222; 95 % CI, $8,222; 95 % CI, 5,020–$11,425; P < .001); (group 2) (difference, $11,425; P < .001); (group 2) (difference, 15,429; 95 % CI, $7,472–$7,472–23,385; P < .001); and (group 3) (difference, $27,077; 95 % CI, $27,077; 95 % CI, 22,901–$31,252; P < .001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences.